Our passion is to make a difference for patients, wherever the need exists.
Genzyme Corporation has enzyme replacement therapy (ERT) for patients with Fabry Disease, Gaucher Disease, MPS I, MPS II and Pompe Disease in the Philippines.
Genzyme Corporation, through the coordination of Director for Souteast Asia Patrick Granjard and Genzyme Philippines Country Manager Jose Santiago A. dela Cruz, Jr., is PSOD’s major partner in providing treatment to patients with Gaucher and Pompe disease. Photo: Fatima and Erika, twins afflicted with Gaucher disease, recipients of Cerezyme (enzyme replacement therapy), pose with
(L-R) Dra. Margarita Jimenez, Genzyme Medical Director, Asia Pacific Group; Dr. Patrick Granjard; Dra. Lynn Silao, Board of Director of PSOD; Vilma Ligsay, mother of the twins; Jose Santiago dela Cruz; and Danilo Ligsay, father of the twins, during the Project Rare Launch, February 25, 2009.
GENZYME is one of the world’s leading biotechnology companies. Its more than 11,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases.
Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2008 revenues of $4.6 billion. Over the past two decades Genzyme has introduced a number of breakthrough treatments in several areas of medicine, which have provided hope to patients who previously had no viable treatment options. Genzyme products are helping patients in 100 countries.
Today, Genzyme continues to be driven by its commitment to patients. The company is working to develop new medicines, improve its existing therapies, secure approvals for its products around the world, and ensure that patients have access to these treatments. Genzyme, which has its headquarters in Cambridge, Massachusetts, was chosen in 2007 to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
Genzyme focuses on the following broad areas of medicine: Genetics Diseases, Oncology, Orthopaedics/Biosurgical Specialties, Transplant, and Genetics/Diagnostics.
Research and Development
Genzyme’s research and development efforts are focused on the areas of medicine where it markets commercial products. The company also conducts research in cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need. In 2008, Genzyme invested approximately $750 million in this work, or about 16 percent of its revenues.
Genzyme continues to build its pipeline through both internal research and licensing and acquisitions, focusing on product candidates with the potential to change the standard of care for serious diseases. The company’s broad pipeline features seven major late-stage programs, including: alemtuzumab for multiple sclerosis; Clolar for adult acute myeloid leukemia; and mipomersen for familial hypercholesterolemia and other high risk, high cholesterol patients.
Corporate responsibility is a priority at Genzyme. The company’s commitment to patients extends beyond the development of new treatments and the services needed to deliver them. Genzyme has a strong presence in developing countries, where it provides free medicine to patients and helps to build sustainable health care systems. The company in 2006 launched an initiative to support the development of treatments for neglected diseases that affect hundred of millions of people in the developing world. Genzyme’s headquarters is one of the most environmentally responsible office buildings in the world, and the company is a leader in waste-reduction and recycling efforts.
In addition, Genzyme supports science education and health initiatives in the communities in which it operates. For these and other efforts, Genzyme has been consistently included in the Dow Jones Sustainability World Index, which consists of companies that excel in economic, environmental and social performance. For the past three years, Genzyme was named one of the “Global 100 Most Sustainable Corporations in the World” by Innovest Strategic Value Advisors. BusinessWeek has ranked Genzyme as one of the top corporate givers, and the company has also been recognized by the U.S. Environmental Protection Agency, the American Association for the Advancement of Science, and many other organizations. (For more info, visit www.genzyme.com)
Institute of Human Genetics
The Institute of Human Genetics (IHG) began in 1990 as the Medical Genetics Unit of the University of the Philippines College of Medicine which in 1999 became as one of the service and research oriented institutes of the National Institutes of Health-University of the Philippines Manila (NIH-UP). Since then all services of the Medical Genetics Unit were transferred to the Institute and is now the largest provider of genetic services in the country.
Today, the IHG houses a clinical genetics unit and four laboratories – Newborn Screening, Cytogenetics, Molecular and Cancer Genetics and Biochemical Genetics; providing both diagnostic and research services with a staff of over 70 consisting of geneticists, physicians, nurses, medical technologists, biochemists, chemists, biologists and administrative support staff.
- Provide services that allow definitive diagnosis and early detection of potentially treatable genetic conditions
- Promote health by understanding the genetic basis of common diseases in the Filipino population through basic and clinical research
- Propagate awareness about common genetic conditions through educational programs among physicians and the general public
- Provide technical information for policy recommendation to help advance the national health agenda
- Cytogenetics Services
- Molecular Genetics
- Biochemical Genetics
- Clinical Genetics
- Newborn Screening
- Birth Defects
- Oral Cleft
- Clefting Genetics
- Cancer Genetics
- Kawasaki Disease
- Cardiovascular Genetics
An internationally-recognized center for excellence in genetics committed to quality research and services accessible to all Filipinos and the world using state-of-the-art and relevant technology
Advance the national health research agenda through genetic services, research, advocacy and policy recommendation
MEAD JOHNSON: A global leader in infant and children’s nutrition
(with excerpts from ‘The Quest to Survive: the Plight of MSUD patients in the Philippines’ by Dory Marco)
Mead Johnson Nutrition is a global leader in infant and children’s nutrition. The company is best known for the Enfamil® and Enfalac® families of infant formulas as well as for regional children’s nutritional products, including Enfagrow®, Enfapro®, Enfakid®, EnfaSchool®, and Sustagen® in Asia, and Choco Milk® and Cal-C-Tose® in Mexico and Latin America.
Mead Johnson was founded more than 100 years ago and has been committed, from its very beginning, to earning the trust of parents and health care professionals by offering scientific evidence of the benefits of our products. That commitment, driven by the pride and passion of its workforce of approximately 5,600 people, is evident today throughout the world. Mead Johnson manufactures and markets more than 70 products in over 50 countries in North America, Latin America, Europe, and Asia-Pacific, and operates major manufacturing facilities in every region where the company conducts business.
With the support of a global company Mead Johnson Philippines continues to innovate in science-based nutrition to nourish current and future generations.
A lifeline for children with MSUD
For the past thirteen years, Mead Johnson supply, free of charge, cans of MSUD Diet Powder formula monthly to support children with MSUD.
In a third world country like the Philippines, the majority of families with MSUD patients do not have the money needed to meet the medical needs of their children, including the special diet powder and special food. Many parents are minimum wage earners, and others are unemployed. Commercially prepared low protein foods such as biscuits and the like can only be availed through the courtesy of relatives residing in the US or Australia, as the high cost of these imported items and the added cost of freight and taxes make them too expensive for most. For example, a can of MSUDpowder (400 gms) cost P2,500- 3,000 or $55-65 American dollars. At present, we are not receiving any subsidy from our government.
Dr. Carmencita Padilla, a pediatric geneticist and director of the Institute of Human Genetics (IHG) of UP-NIH, feeling the burden of the families with MSUD Children, tried to find ways of helping parents by networking with local formula companies and the Department of Health. Through her efforts, Mead Johnson Philippines, thru its Director for Corporate Affairs Mila Llorin and its Corporate Affairs Manager Judd Salas, committed to facilitate the donation of MSUD diet powder to affected children from their mother company based in the US. They have been providing the needed special diet milk for over three years now.
Extending support to patients with PKU and MMA
For over a year now, Mead Johnson Philippines has been faciliating the monthly donation of 12 cans of phenylalanine-free and iron-fortified dietary powder for infants and toddlers with phenylketonuria (PKU), another inborn metabolic disorder. For a time, too, Mead Johnson Philippines facilitated the donation of a special formula for IHG patients with MMA who was then admitted at the Philippine General Hospital. Hopefully, Mead Johnson will be able to include theMMA special milk in their donation package.
Join our mailing list to receive updates straight to your inbox.